The milestone payment is partially funded through Sarepta’s Arrowhead stock sale as both companies push forward with ...

Sarepta’s troubles had nothing to do with Arrowhead’s assets, and yet both companies have seen their stock prices decline ...

A team of researchers from the Spanish National Research Council has made a significant advance in plant biotechnology by ...

HHS is slashing hundreds of millions in funding for mRNA vaccines and infectious disease treatments, but leaving the door ...

Immunotherapy employs patients' own immune systems to fight cancer, and it has shown itself to be an effective treatment in ...

Reprogrammable RNA nanoparticles activate only in cancer cells to deliver targeted gene-silencing therapy while avoiding ...

Sarepta Therapeutics sells 9.3M Arrowhead shares for $174M and fulfills a $100M milestone payment. Read more here.

We recently compiled a list of 11 Best Future Stocks to Buy Now. Arrowhead Pharmaceuticals, Inc. stands seventh on our list. Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is a biotechnology company ...

Anastasia Khvorova’s lab at the University of Massachusetts Chan Medical School shows how quickly the administration is ...

MicroRNAs (miRNAs) are tiny RNA molecules that regulate gene expression by controlling messenger RNAs (mRNAs) and are ...

The Japanese rhinoceros beetle, Trypoxylus dichotomus, is a large insect native to Asia, characterized by the large horn of ...

Sarepta Therapeutics is selling off Arrowhead Pharmaceuticals’ shares to stretch its cash runway, while also inking a share ...